{"id":"W4286512869","doi":"10.1016/j.annonc.2022.05.183","title":"MO31-4 Phase 1b/2 trial of tucatinib+trastuzumab+/-chemotherapy or pembrolizumab in patients with metastatic HER2+ GI cancers","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Seagen (Canada)","funders":"","keywords":"Medicine; Trastuzumab; Pembrolizumab; Oncology; Internal medicine; Chemotherapy; Cancer; Immunotherapy; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001056978,0.001463002,0.002043108,0.0004158179,0.0004125866,0.001188538,0.00081535,0.001199871,0.006945956],"category_scores_gemma":[0.0006384332,0.0005732747,0.001611963,0.0003384295,0.000900191,0.0009556058,0.0004077631,0.003293585,0.001064173],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001518459,"about_ca_system_score_gemma":0.001723345,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002149968,"about_ca_topic_score_gemma":0.008465468,"domain_scores_codex":[0.999721,0.0001164397,0.000009797819,0.0000427029,0.00001693273,0.00009316255],"domain_scores_gemma":[0.9997354,0.00003745226,0.0000471458,0.00001948847,0.00001402022,0.0001463961],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.77936,0.01583453,0.00340138,0.001328492,0.001684244,0.000216867,0.0001957911,0.004039805,0.02442515,0.0009150884,0.01293208,0.1556666],"study_design_scores_gemma":[0.8390831,0.1395904,0.009239909,0.0001017185,0.0006394627,0.0002896594,0.00006374998,0.001545162,0.002213363,0.0006705306,0.006524523,0.00003829377],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814636,0.006227908,0.0004618169,0.002496254,0.0004965165,0.002018454,0.00181262,0.0002461152,0.004776706],"genre_scores_gemma":[0.971157,0.005559811,0.00225264,0.002224059,0.0003594951,0.002287732,0.004653251,0.00007506851,0.01143116],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006945956,"threshold_uncertainty_score":0.02323657,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05416364070373584,"score_gpt":0.4149781590378478,"score_spread":0.360814518334112,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}